-$1.04 Earnings Per Share Expected for Spero Therapeutics Inc (NASDAQ:SPRO) This Quarter
Brokerages predict that Spero Therapeutics Inc (NASDAQ:SPRO) will post ($1.04) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($1.23) and the highest is ($0.92). Spero Therapeutics posted earnings of ($0.60) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 73.3%. The company is scheduled to issue its next quarterly earnings report on Thursday, March 12th.
According to Zacks, analysts expect that Spero Therapeutics will report full-year earnings of ($3.11) per share for the current fiscal year, with EPS estimates ranging from ($3.34) to ($2.94). For the next fiscal year, analysts forecast that the company will post earnings of ($3.65) per share, with EPS estimates ranging from ($5.27) to ($3.01). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Monday, November 4th. The company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.10). Spero Therapeutics had a negative return on equity of 43.10% and a negative net margin of 287.11%. The business had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $2.03 million.
Hedge funds and other institutional investors have recently modified their holdings of the business. Marshall Wace LLP purchased a new stake in shares of Spero Therapeutics during the first quarter worth approximately $39,000. Wells Fargo & Company MN raised its stake in shares of Spero Therapeutics by 187.9% during the second quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after purchasing an additional 8,915 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Spero Therapeutics by 9.2% during the second quarter. JPMorgan Chase & Co. now owns 164,389 shares of the company’s stock worth $1,826,000 after purchasing an additional 13,814 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Spero Therapeutics during the second quarter worth approximately $25,000. Finally, AWM Investment Company Inc. raised its stake in shares of Spero Therapeutics by 6.4% during the second quarter. AWM Investment Company Inc. now owns 598,315 shares of the company’s stock worth $6,887,000 after purchasing an additional 36,019 shares during the last quarter. Institutional investors own 50.98% of the company’s stock.
Spero Therapeutics stock traded down $0.04 during trading hours on Thursday, hitting $10.22. 21,200 shares of the stock traded hands, compared to its average volume of 26,086. Spero Therapeutics has a 1 year low of $5.52 and a 1 year high of $14.48. The stock has a market capitalization of $196.26 million, a price-to-earnings ratio of -3.93 and a beta of 2.09. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.90 and a quick ratio of 6.90. The firm’s 50 day moving average price is $10.67 and its 200-day moving average price is $10.93.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Featured Article: Understanding Market Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.